GSK has turned to Brooke Shields to get the message ... and we've been able to penetrate those populations to a very high degree. In our number one segment, we're around 66% penetration ...
GSK Says mRNA Flu Shot Shows Promise in Boost for Pipeline GSK could beat Pfizer to market, says chief commercial officer Several drugmakers are betting on mRNA seasonal flu vaccines ...
GSK wins latest trial over Zantac cancer claims August 5, 2024 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of ...
GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...
(Reuters) - British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any ...
After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all ...
(RTTNews) - Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple myeloma have been accepted for regulatory review in ...
(Reuters) -British drugmaker GSK announced on Thursday positive results from a mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, and said it ...
Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...
A look at the top 25 high school football teams in the Southland heading into Week 4 of the season. Sophomore quarterback is a dynamic playmaker with plenty of weapons among his teammates.
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial, keeping the drugmaker in the race to bring the technology to ...